The pursuit by the FSCS and FSA of advisers who recommended Keydata products looks set to create a domino effect that will cascade far and wide.
The FSA has proposed a ban on traded life policy investments (TLPIs), arguing the products “provide no benefit to investors”. This total censure comes hot on the heels of a decision by the FSCS to recover some of the £327m it paid out in the highest profile failure of the TLPI market Keydata, by pursuing through the courts advisers who recommended it. Emotions are running high. Time then for a sober reflection on what the two decisions mean. In a nutshell, it is very likely all advisers will pay a financial price for TLPIs’ troubled existence in the market place. The FSCS’ pursuit...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes